10-Q: Bakhu Holdings Reports Q3 2024 Results Amidst Restatement and Financial Challenges

Bakhu Holdings reports no revenue for Q3 2024, a net loss of $906,837, and ongoing efforts to secure additional funding while addressing significant liabilities.

Summary

• Bakhu Holdings, Corp. reported its financial results for the third quarter of 2024, ending April 30, 2024.
• The company did not generate any revenue during the three and nine months ended April 30, 2024 and 2023.
• The net loss for the three months ended April 30, 2024 was $906,837, compared to a net loss of $2,142,833 for the same period in 2023.
• For the nine months ended April 30, 2024, the net loss was $2,158,995, compared to a net loss of $9,054,449 for the same period in 2023.
• The company's total liabilities were $10,747,336, with current liabilities at $2,933,520, and total assets at $519,477.
• The company has an accumulated deficit of $49,638,483 as of April 30, 2024.
• The company is seeking between $9.0 and $19.0 million through the sale of convertible secured notes to reduce liabilities and fund operations.
• The financial statements for the three and nine months ended April 30, 2023, were restated to correct consulting fees expense related to warrants issued.
• The company is currently insolvent and may be subject to judicially supervised reorganization or liquidation proceedings.

Sentiment

Score: 2

Explanation: The document reveals significant financial distress, lack of revenue, and ongoing operational challenges, indicating a very negative outlook from an investment perspective. While there are some positive changes in management and governance, the overall financial situation is dire.

Positives

• The company recorded a gain on settlement of debt of $323,078 during the nine months ended April 30, 2024.
• Consulting fees decreased significantly in the current period, reflecting reduced activities due to funding shortages.
• The company has secured $1,030,000 in funding through the sale of convertible secured notes in Tranche 1.
• The company has expanded its board of directors with the appointment of three new members with significant industry experience.
• The company has appointed a new President and CEO, Dr. Teddy Scott, and a new Chairman of the Board, Mitch Kahn.

Negatives

• The company has not generated any revenue to date.
• The company is currently insolvent and unable to pay its liabilities as they become due.
• The company has a significant accumulated deficit of $49,638,483.
• The company has a working capital deficit of $2,930,329.
• A substantial portion of the company's current liabilities are over 30 days past due, with some over 18 months past due.
• The company's ability to continue as a going concern is dependent on securing additional capital.
• The company's internal controls are not effective due to a lack of segregation of duties and other control procedures.
• The company has restated its financial statements for the three and nine months ended April 30, 2023, due to errors in expensing warrants.

Risks

• The company's insolvency could lead to judicially supervised reorganization or liquidation proceedings.
• The company's ability to continue as a going concern is contingent on securing additional capital.
• The company's lack of revenue and significant liabilities pose a substantial risk to its operations.
• The company's internal control weaknesses could lead to further financial reporting issues.
• The company's dependence on related party loans and notes payable could create conflicts of interest.
• The company's efforts to commercialize its technology may be delayed or negatively impacted by world political and military exigencies.
• The company's inability to secure additional funding may lead to cost-cutting measures and delays in planned activities.
• The company's reliance on convertible debt financing could result in substantial dilution to existing shareholders.

Future Outlook

The company intends to commercialize its licensed technology through joint ventures, strategic partners, sublicenses, and other arrangements, and is seeking additional capital to fund these efforts. The company is also seeking to reduce its liabilities and fund its proposed activities through the sale of convertible secured notes.

Management Comments

• Management believes that the assumptions made and expectations reflected in the forward-looking statements are reasonable.
• Management acknowledges the company is insolvent and may be subject to judicially supervised reorganization or liquidation proceedings.
• Management states that the company is seeking between $9.0 and $19.0 million through the sale of convertible secured notes.
• Management notes that the company's recently expanded board of directors is reviewing the business plan and estimated funding requirements.
• Management states that the company expects to eventually generate revenue pursuant to its commercialization and licensing efforts, dependent on obtaining additional capital.

Industry Context

The company operates in the cannabis industry, which is subject to evolving regulations and market dynamics. The company's focus on cell-extraction and replication technology positions it within a niche area of the industry, but it faces competition from other companies in the cannabinoid production space. The company's financial challenges highlight the risks associated with early-stage companies in this sector.

Comparison to Industry Standards

• The company's lack of revenue is a significant deviation from industry standards for companies that have been operating for several years.
• The company's high level of debt and accumulated deficit are concerning compared to industry benchmarks.
• The company's reliance on related party loans is not uncommon in early-stage companies but raises concerns about potential conflicts of interest.
• The company's restatement of financial statements indicates a lack of robust internal controls, which is a concern compared to industry best practices.
• The company's efforts to secure funding through convertible debt are common in the cannabis industry, but the terms and conditions of these notes can vary significantly.
• Compared to companies like Curaleaf Holdings, which acquired Grassroots Cannabis, Bakhu is significantly behind in terms of revenue generation and market presence.
• The company's technology, while potentially innovative, has not yet translated into commercial success, unlike companies with established production and distribution networks.

Management Changes

Corporate Governance

Related Party Transactions

• The company has significant notes payable to related parties, including Cell Science Holding Ltd. and The OZ Corporation.
• The company has an Office Cost Sharing Agreement with The OZ Corporation, with $1,307,000 due for unpaid space sharing fees as of April 30, 2024.
• The company's CEO and CFO are also officers and directors of related parties.
• The company's largest stockholder, Inter-M Traders FZ LLE, is a related party.
• The company's lead investor in the convertible note offering is The OZ Company and its owner, John R. Munoz, a principal stockholder.

Stakeholder Impact

• Shareholders face significant risk of dilution and potential loss of investment due to the company's financial difficulties.
• Employees may be impacted by cost-cutting measures and potential delays in planned activities.
• Creditors face the risk of non-payment and potential insolvency proceedings.
• Customers and suppliers are not directly impacted at this stage due to the company's lack of revenue and commercial operations.
• The company's intellectual property licensor, Cell Science, is a key stakeholder due to the company's reliance on the licensed technology and related debt.

Next Steps

• The company will continue to seek additional funding through the sale of convertible secured notes.
• The company will allocate a portion of the incoming funds to repay current liabilities and operating expenses.
• The company will review its business plan and estimated funding requirements.
• The company will continue to work on commercializing its licensed technology.
• The company will seek to negotiate extended or discounted payments for many of its creditors.

Key Dates

Keywords

cannabinoids, bioreactor, technology license, convertible notes, financial statements, restatement, insolvency, stock options, funding, debt